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Abstract 
Introduction: Heart failure (HF) is an unusual heart function that causes reduction in cardiac or pulmonary output. 
Cardiac resynchronization therapy (CRT) is a mechanical device that helps to recover ventricular dysfunction by pac-
ing the ventricles. This study planned to systematically review cost-effectiveness of CRT combined with an implant-
able cardioverter-defibrillator (ICD) versus ICD in patients with HF.
Methods: We used five databases (NHS Economic Evaluation Database, Cochrane Library, Medline, PubMed, and 
Scopus) to systematically reviewed studies published in the English language on the cost-effectiveness of CRT with 
defibrillator (CRT-D) Vs. ICD in patients with HF over 2000 to 2020. Consolidated Health Economic Evaluation Report-
ing Standards (CHEERS) checklist was applied to assess the quality of the selected studies.
Results: Five studies reporting the cost-effectiveness of CRT-D vs ICD were finally identified. The results revealed 
that time horizon, direct medical costs, type of model, discount rate, and sensitivity analysis obviously mentioned in 
almost all studies. All studies used quality-adjusted life years (QALYs) as an effectiveness measurement. The highest 
and the lowest Incremental cost-effectiveness ratio (ICER) were reported in the USA ($138,649per QALY) and the UK 
($41,787per QALY), respectively.
Conclusion: Result of the study showed that CRT-D compared to ICD alone was the most cost-effective treatment in 
patients with HF.
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Introduction
Heart failure (HF) is one of the most common and dead-
liest disease that consumes the highest rate of health 
expenditure in the world [1, 2]. It is a set of clinical syn-
dromes in which abnormal cardiac function leads to a 
decrease in cardiac or pulmonary output or persistent 
chest pain [3]. Each year, approximately 3.5 million 
people suffer from HF worldwide, and if left untreated, 
after one year, death rate rises to about 40 percent [4–7]. 
According to the European Society of Cardiology (ESC), 
costs of HF are very high, reaching up to 2% of the total 
health costs in the developed countries [8].
It is predicted that the total HF cost will increase to 
$69.7 billion in 2030 worldwide [9].
According to clinical guidelines, there are several 
procedures to improve HF patient’s conditions. Cardiac 
pacemakers are one of the mechanical devices used to 
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recover heart function [10]. Pacemakers are made of a 
generator with a small battery which is connected to 
one or more electrical leads. As soon as the normal 
heart rate decreases, these pacemakers transfer electri-
cal waves from the generator to the ventricles or atria 
and cause a series of atrial and ventricular contrac-
tions [11]. In HF patients, based on some clinical fac-
tors such as, left ventricular ejection fraction (LVEF), 
ischemic etiology status, QRS duration and New York 
Heart Association (NYHA) class, Cardiac resynchro-
nization therapy (CRT) helps to recover ventricular 
dysfunction through pacing the right and left ventri-
cles concurrently [12–15]. Existing clinical guidelines 
recommend CRT in patients with moderate-to-severe 
heart failure (NYHA class III–IV), LVEF (≤ 35%) and 
delayed intraventricular conduction evidenced by a 
wide QRS complex. Also, the most important clinically 
question about CRT is whether adding CRT capabil-
ity to implantable cardioverter-defibrillator (ICD) is 
marginally cost-effective. The National Institute for 
Health and Care Excellence (NICE) recommends CRT 
combined with an implantable cardioverter-defibrilla-
tor (CRT-D) to improve outcomes in HF patients with 
NYHA class II- IV with low ejection fraction (≤ 35%) 
and wide QRS [16, 17].
Due to the high economic burden of heart disease as 
well as the limited financial resources, not only does it 
impact individual patient cost, but also the health care 
system. According to the Dhvani Shah et al. (2020), CRT, 
CRT-D and ICD devices related cost in US dollars, is $ 
17,982, $ 36,153 and $ 23,317 respectively [26]. Several 
studies have done cost-effectiveness of CRT in HF. But 
to date, no study systemically reviewed quality appraisal 
of cost-effectiveness of CRT combined with ICD. So this 
study developed to systematically review cost-effective-




This systematic review was conducted to assess articles 
on the cost-effectiveness of CRT combined with an ICD 
versus ICD alone in patients with HF between January 
2000 and July 2020. A literature search was performed 
through five reliable databases including NHS Economic 
Evaluation Database, Cochrane Library, Medline, Pub-
Med, and Scopus. Keywords for searching and identify-
ing relevant studies were: cost-effectiveness or cost-utility 
or cost-benefit or economic evaluation and heart failure 
or cardiac failure or myocardial failure or heart decom-
pensation and implantable cardioverter defibrillator or 
cardiac resynchronization therapy.
Inclusion and exclusion criteria
Inclusion criteria for studies were: original researches 
which performed a full economic evaluation, contained 
cost-effectiveness analysis, cost-utility analysis or 
cost-benefit analysis, articles which expressed quality-
adjusted life years (QALYs), life-years gained or prehos-
pitalization as their outcomes measures. Also studies 
that evaluated CRT combined with an ICD versus ICD 
alone in patients with HF, and articles published in the 
English language during 2000 to 2020.
Also, the exclusion criteria were: studies with a par-
tial economic evaluation (such as those evaluating 
effectiveness, evaluating costs, and assessing the qual-
ity of life, review and meta-analyses articles, studies 
published as abstracts only, case reports, conferences 
papers, and low-quality studies according to the Con-
solidated Health Economic Evaluation Reporting 
Standards (CHEERS) checklist.
Quality assessment of the methodology of the studies
The CHEERS statement was used to assess the report-
ing quality of studies. This checklist consists of 24 
recommendations that evaluate the quality of meth-
odology of health care economic assessment studies 
in the following items: Heading and summary, content 
and aims, study population and subcategories, place of 
study, study perspective, comparators, time horizon, 
discount amount, select of health outcomes, assess-
ment of effectiveness, measurement and estimate of 
preference-based outcomes estimating resources and 
costs, currency, type of model, assumptions, analyti-
cal methods, study parameters, incremental costs and 
effects, characterizing uncertainty, characterizing het-
erogeneity, discussion, source of funding, and disclo-
sures [18]. After searching the studies, the selected 
articles were assessed by two researchers in terms of 
the quality of methodology using the CHEERS check-
list. Disagreements among two primary reviewers were 
solved by the third researcher. Finally, according to the 
CHEERS checklist, the quality score of each study was 
reported as a percentage (%) out of a total of 24 items.
Data analysis
Designed data collection forms were used to extract 
and summarize the required information from the 
selected studies. Endnote version X7.7 software was 
used to organize the studies, read the titles, abstracts, 
and identify duplicates articles. Final selected studies in 
this review reported a wide range of incremental cost-
effectiveness ratio (ICER). In order to compare different 
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ICER, all of them were inflated by 2020 at an annual 
rate of 3% [19].
Results
Search results
A total of 211 studies were identified; duplicated studies 
were deleted. Then 29 studies were excluded based on 
the exclusion criteria. A full-text review was conducted 
for remained articles and 61 of them were excluded. 
Ultimately, we selected and evaluated the results of five 
studies with full economic evaluation (cost-effectiveness) 
of CRT combined with an ICD versus ICD in patients 
with HF [20–24]. The results of the systematic review are 
shown in Fig. 1.
Study characteristics
Characteristics of five selected articles are summarized 
according to the designed data collection form as follows: 
first author of the study, country setting, published year, 
study population, comparator, effectiveness measure, 
time horizon, type of model used for data analysis, per-
spective of the study, type of cost used in analysis, type 
Fig. 1 Search results and study selection and inclusion process
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of sensitivity analysis, the discount rate for costs and 
effectiveness, and the incremental cost-effectiveness ratio 
(ICER) (Table 1).
Final five studies in this review have different cost and 
effectiveness analysis methods, different viewpoints, and 
different population size in cost-effectiveness evaluation. 
Also, history and follow-up duration time of patients are 
dissimilar. Moreover, the value of health spending and 
the opportunity cost are different between countries. 
Finally, only English language studies were used in the 
study inclusion, which means that articles from other 
languages might have been omitted.
Result of our study revealed that selected studies were 
conducted in the United States, the United Kingdom, 
and Brazil. Two studies used the Markov model [20, 23], 
one study used the decision tree model [22], and in one 
study, type of model was not mentioned [21]. However, in 
one study type of model was the Cohort survival model 
[24]. Discount rate for cost and effectiveness, study per-
spective, and time horizon of the study were included 
in all studies. In four studies, discount rate was 3%-3.5% 
[20–22, 24] while in one study it was 5% [23]. Also, all 
studies used QALY as effectiveness measurement and 
in three studies life-years gained added to QALY [20, 21, 
24]. Among the final five studies, three of them concur-
rently conducted deterministic and probabilistic sensitiv-
ity analyses [21, 23, 24]. But in two studies deterministic 
sensitivity analyses were used [21, 23]. Usually, the sen-
sitivity analysis method is used to measure the effect of 
uncertainty on results and also the generalizability of 
findings [25–29]. Governmental perspective was used in 
four studies [21–24] but in one study it was societal [20].
Results from the current study also revealed that all 
studies applied direct medical costs in their analysis but 
direct non-medical costs and indirect costs did not con-
tain in these studies.
As a final point, after standardizing value of ICER in 
selected studies, the highest and the lowest Incremental 
cost-effectiveness ratio (ICER) were reported in the USA 
($138,649per QALY) and the UK ($41,787per QALY), 
respectively [20, 22].(Table 1).
Also, result of the CHEERS checklist stated that Meal-
ing et  al. had the highest satisfied percent (100%) [22] 
and Woo et al. had the lowest one (88%) [20]. Moreover, 
Bertoldi et  al., Noys et  al., and Dhvani Shah et  al. had 
96, 92, and 83 satisfied percent respectively [21, 23, 24]. 
(Table 2).
We also stated other characteristics of the selected 
studies including: subsections on costs, resource use, 
methods for HRQOL, methods for treatment effect, 
summary of health states, life years gained, time in each 
health state, number of events and Study Calculation 
Method in Table  3. For example, methods for HRQOL 
in all five selected studies was EQ-5D. Study Calculation 
Method in Two studies was Regression equations [22, 24] 
while in three studies it was ICER [20, 21, 23]. The High-
est and the lowest life years gain of CRT-D vs ICD were 
mentioned in Woo et al. (9.8 years) and Noys et al. (3.61 
years) respectively [20, 21]. Methods for treatment effect 
in four studies was meta–analysis [20, 22–24] and in one 
study it was MADIT-CRT study [21] (Table 3).
We noticed that Dhvani Shah et al. has used underlying 
economic model of Mealing et al. in different perspective, 
effectiveness measure and discount rate.
Discussion
This systematic review evaluated the results of five rel-
evant articles which concluded CRT plus ICD in HF 
patients might be more cost-effective than ICD alone. 
It means that if policy makers want to use results of our 
study, they should consider to the clinical heterogeneity 
in different patient groups. Cost-effectiveness analysis is 
a method to measure resource consumption related to 
a health intervention. In these studies, a specific health 
care intervention is compared with available alternatives 
in terms of effectiveness and costs. This helps to better 
resource allocation in the health care system.
There are two types of CRT devices: biventricular pace-
maker CRT, and biventricular pacemaker with defibril-
lator CRT-D. Also, ICD is a cardiac defibrillator [30]. In 
patient with HF, most of the candidates for CRT devices 
also have an indication for an ICD. So these patients most 
commonly receive a CRT-D device compared to a CRT 
[31]. Results of some researches showed that CRT-D 
implantation was highly prevalent (≥ 75%) in subgroups 
that ICD benefit may be reduced (older adults with mul-
tiple comorbidities) [32].
The results of our study showed that utility values 
used in the selected studies were extracted from litera-
ture review findings which could not exactly reflect the 
QALY score. However, ICER Values were reported dif-
ferently from one study to another. According to Woo 
et  al. (2015), ICER was $119,600 per QALY [20]. Noys 
et al. (2013) reported it as $58,330 per QALY [21]. ICER 
was estimated $ 36,940 per QALY by Bertoldi et al. [23]. 







Dhvani Shah et al. (2020) 22 24 92%
Mealing et al. (2016) 24 24 100%
Woo et al. (2015) 21 24 88%
Bertoldi et al. (2013) 23 24 96%
Noys et al. (2013) 22 24 92%
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Dhvani Shah et  al. showed that ICER was $100,000 per 
QALY [24].
In cost-effectiveness studies, ICER may be affected 
by several factors, such as age and gender of population 
study, threshold values in different countries, heart dis-
eases epidemiology, costs and effectiveness measurement 
methods, and fees of intervention and medical equip-
ment in different countries [33].
Moreover, based on the results of the current system-
atic review, more expensive CRT-D devices, shorter 
CRT-D battery life, and older age of patients made the 
cost-effectiveness of CRT-D less advantageous.
Also finding of our study showed that using CRT-D 
increased effectiveness and reduced costs. Mealing et al. 
showed that CRT-D reduced monthly hospitalization rate 
by 30% while ICDs decreased monthly hospitalization 
rates by 20% [22]. Woo et  al. also revealed that CRT-D 
increased life expectancy (9.8 years versus 8.8 years) 
and QALYs (8.6 years versus 7.6 years) compared with 
implantation of an ICD alone [20]. Bertoldi et al. showed 
that in more flexible healthcare budgets system, CRT-D 
would be a more attractive option than ICD alone. It 
means that CRT-D is the preferred strategy in the most 
liberal budgets (CRT-D is preferred compared to ICD 
with WTP thresholds above Int$ 35,000). In fact, if the 
cost of the CRT-D devices was lowered or their battery 
longevity increased, it would become a more attractive 
option, with an acceptable ICER considering the World 
Health Organization WTP threshold [23].
In most studies, major cost drivers were physicians, 
drugs, diagnostic tests and procedures cost, and also hos-
pitalization costs related to device implantation. Also, 
results of this systematic review showed that studied 
population was asymptomatic patients with a left ven-
tricular ejection fraction (LVEF) of 30% or less and QRS 
duration of 120 ms or more in almost studies. Moreover, 
results revealed that although early device implantation 
imposed some cost on patient, survival rate increased in 
their lifetime.
Conclusion
CRT-D compared with ICD alone was cost-effective 
treatment for HF. Also, because the prevalence of HF is 
high in poor-income countries, it seems more studies 
should be conducted on the economic evaluation of CRT-
D. Because of growing use of cardiac devices especially 
ICD in low and middle-income countries, the results of 
our study can be useful for policymakers and HF treat-
ment centers in that countries to apply experiences of 
developed nations if they want to expand cardiac devices 
surgeries in the future. Thus, policymakers and clini-
cal specialists in their studies in low and middle-income 
countries should be noted to different epidemiology and 
economic circumstance in their setting.
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